← Oncology Approval Tracker

FDA DECISION ·

Enhertu

fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with unresectable or metastatic HR-positive breast cancer with HER2-low (IHC 1+ or IHC 2+/ISH-negative) or HER2-ultralow (IHC 0 with membrane staining) disease on an FDA-approved test, after progression on at least one endocrine therapy in the metastatic setting.

LAMPGEN ANALYSIS

Why it matters

This action extended the indication to HER2-ultralow disease and moved treatment earlier for eligible endocrine-pretreated patients.

What research teams should watch

Ensure pathology reports distinguish faint membrane staining from no staining and that prior endocrine treatment is documented.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

HER2-selected breast cancer

PRIMARY RECORDS

Sources